Skip to main content
padlock icon - secure page this page is secure

A New Biomarker with High Outcome Prediction in IgA Nephropathy

Buy Article:

$68.00 + tax (Refund Policy)

Biomarkers able to predict progression and treatment responsiveness are of paramount importance in glomerulonephritis. In IgA Nephropathy (IgAN) at present the most powerful prognostic predictor is the level of proteinuria; the predictive value of proteinuria may be enhanced by measurement of its high molecular weight components which are reliable markers of alteration of glomerular filtration barrier. Aim of the review is to summarize recent literature on predictive value of functional outcome in IgAN patients of the new biomarker FE IgG/SG: Fractional Excretion of IgG divided by non obsolescent glomeruli defined Surviving Glomeruli (SG). In 132 non-crescentic IgAN patients, FE IgG/SG < vs ≥ 0.00010 predicts progression (ESRD and eGFR reduction ≥50%) in 2% vs 87.5% of 68 untreated and in 0%vs36% of 64 patients treated with ACE-inhibitors. In patients with SG < 80% (57 + 14%) progression rate is 100% vs 0% if FE IgG/SG is ≥ vs < 0.00010. In 34 crescentic IgAN patients FE IgG/SG < vs ≥ 0.00034 predicts progression in 5%vs83% and in 0%vs89% of 23 patients treated with Steroids and Cyclophosphamide. In patients with FE IgG/SG ≥ 0.00034 and sCr ≥ 1.74 mg/dL progression prediction is 100%. In conclusion this biomarker based on combination of Fractional Excretion of the high MW protein IgG with nephron loss is a powerful outcome predictor in IgAN patients and represents a validation in a human disease of some progressive mechanisms hypothesized by the “remnant kidney” progression theory. The review also outlines some recent patents on the biomarkers for nephropathy.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: ACE-inhibitors; Fractional excretion of IgG; GLOBAL GLOMERULOSCLEROSIS; IgA nephropathy; PROTEINURIA; PROTEINURIC BIOMARKER; chronic renal failure; outcome prediction; surviving glomeruli (SG); tubulo-interstitial damage

Document Type: Research Article

Publication date: May 1, 2012

More about this publication?
  • Recent Patents on Biomarkers publishes review and research articles, and guest edited thematic issues on important recent patents on biomarkers. The coverage includes novel biomarkers in basic, medical, environmental, and pharmaceutical research. A selection of important and recent patents on biomarkers is also included in the journal. The journal is essential reading for all researchers involved in biomarker research and discovery. The journal also covers recent research (where patents have been registered) in fast emerging patent biomarker applications; discovery and validation are covered for drug discovery, clinical development and molecular diagnostics.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more